Derrick Sung is the Chief Operating Officer and Chief Financial Officer at Pulmonx Corp, a medical technology company pioneering minimally invasive solutions for severe lung diseases, including its landmark Zephyr Endobronchial Valve for emphysema treatment. With more than 20 years of experience in the medical device and biotechnology sectors, Derrick has built a distinguished career in finance, operations, and strategic growth. Prior to Pulmonx, he served as Vice President of Finance and Treasurer at Nevro Corp, where he orchestrated the company's initial public offering on NASDAQ and spearheaded post-IPO financial strategies that fueled rapid expansion. His earlier roles included key finance positions at Shockwave Medical, Integra LifeSciences, and Boston Scientific, where he excelled in financial planning, treasury management, and cross-functional leadership. Derrick joined Pulmonx in 2020 as Chief Financial Officer and ascended to COO in 2023, bringing his proven track record to support the company's ambitious growth trajectory. His achievements include securing over $200 million in equity financings, optimizing global supply chain operations, and enhancing financial controls amid rapid commercialization. Under his guidance, Pulmonx achieved significant milestones, such as expanded FDA approvals, European market penetration, and improved revenue growth, solidifying its leadership in respiratory care innovation. In his dual role, Derrick oversees finance, operations, investor relations, and corporate development, ensuring operational efficiency and fiscal discipline align with Pulmonx's mission to transform patient outcomes. His strategic foresight and hands-on approach continue to drive sustainable profitability and long-term value creation for stakeholders.